Here are 1-3 brief analogies for Vaxcyte (PCVX):

• Moderna for bacterial vaccines.

• Merck, but exclusively for next-generation vaccines.

• VAX-24: A 24-valent pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease.
• VaxCyn: A vaccine candidate designed to prevent infections caused by *Pseudomonas aeruginosa*.
• VCV-01: A vaccine candidate being developed to target *Shigella* infections.

Vaxcyte (PCVX) Major Customers

Vaxcyte (PCVX) is a clinical-stage biotechnology company focused on developing novel conjugate vaccines. As such, the company does not currently have any commercial products on the market from which it generates revenue through sales to customers. Therefore, Vaxcyte does not have "major customers" in the traditional sense, whether they be other companies or individual consumers.

The company's operations are primarily funded through equity financing. While Vaxcyte has previously received grant funding for specific development programs (e.g., from the Bill & Melinda Gates Foundation), these represent strategic collaborations and funding sources rather than traditional customer relationships for product sales.

• Lonza (LONN)

Grant Pickering
Chief Executive Officer, Director and Co-Founder

Grant Pickering co-founded Vaxcyte in 2013 and has over 30 years of experience in pharmaceutical and biotech, covering vaccines and immunotherapeutic drug development and commercialization. Prior to Vaxcyte, he served as CEO of Mymetics Corporation, a European-based vaccine company. He was also CEO at Juvaris BioTherapeutics, where its platform led to animal health products (Zelnate® and Victrio®) launched by Bayer HealthCare. Pickering played a significant role in Dendreon Corporation's IPO and the launch of the therapeutic prostate cancer vaccine, Provenge®. He also led marketing and business development for Algos Pharmaceutical Corporation, which was acquired by Endo Pharmaceuticals.

Andrew Guggenhime
President and Chief Financial Officer

Andrew Guggenhime joined Vaxcyte in May 2020 as CFO and COO, and was promoted to President and CFO in January 2021. His 30-year career spans biotech and financial services, with broad expertise in strategy, finance, operations, investor relations, and corporate development. Before Vaxcyte, he was Chief Financial Officer of Dermira, Inc. through its acquisition by Eli Lilly and Company, where he managed financings, including its IPO, and scaled the company. Guggenhime also served as CFO for several other biotech companies that were acquired: Calistoga Pharmaceuticals, Inc. (acquired by Gilead Sciences, Inc.), Facet Biotech Corporation (acquired by Abbott Laboratories), and Neoforma, Inc. (acquired by Global Healthcare Exchange, LLC). He began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company.

Jim Wassil, MS, MBA
Executive Vice President and Chief Operating Officer

Jim Wassil serves as the Executive Vice President and Chief Operating Officer at Vaxcyte.

Harp Dhaliwal, MBA
Chief Technical Operations Officer

Harp Dhaliwal brings 25 years of experience in engineering, operations strategy, manufacturing, and supply chain within the healthcare industry. Prior to joining Vaxcyte, he served as Senior Vice President of Supply Chain, Manufacturing and Procurement at Dermira, transitioning to Eli Lilly following its acquisition.

Jeff Fairman, PhD
Vice President, Research and Co-Founder

Jeff Fairman is a co-founder of Vaxcyte and has over 25 years of experience in biotech, leading research efforts at various platform companies. Before co-founding Vaxcyte, he was the founder and Vice President of Research at Juvaris BioTherapeutics, where he developed an immunotherapeutic and vaccine adjuvant platform that produced animal health products, including Zelnate® and Victrio®, which were later launched by Bayer HealthCare.

Vaxcyte (PCVX) is a clinical-stage vaccine innovation company primarily focused on developing pneumococcal conjugate vaccines (PCVs) for the prevention of invasive pneumococcal disease (IPD). The company's main product candidates in advanced development are VAX-24 and VAX-31.

The total addressable market for the pneumococcal vaccine market is projected to reach $13.3 billion by 2033. Another estimate places the global pneumococcal vaccine market at $6.2 billion, with an annual growth rate of 5%. Specifically for invasive pneumococcal disease, the market size is expected to reach $11.6 billion by 2035.

For Vaxcyte's individual product candidates:

• VAX-31: This 31-valent PCV candidate is designed to prevent IPD in adults and infants. It has the potential to cover approximately 95% of IPD circulating in the U.S. adult population and approximately 94% of IPD in children under five years of age in the United States.
• VAX-24: This 24-valent PCV candidate is being developed for the prevention of IPD, particularly in infants. It is designed to cover more serotypes than any infant PCV currently on the market. Annual revenue for VAX-24 is expected to reach $287 million by 2039 in the U.S. One projection also indicates a peak sales estimate of $2.27 billion for VAX-24.

Vaxcyte also has earlier-stage vaccine candidates targeting Group A Strep, periodontal disease (VAX-PG), and Shigella (VAX-GI).

Here are the 3-5 expected drivers of future revenue growth for Vaxcyte (PCVX) over the next 2-3 years:

1. Commercialization of VAX-31 for Adult Invasive Pneumococcal Disease (IPD): Vaxcyte's most advanced program, VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate, is expected to initiate a pivotal Phase 3 non-inferiority study in December 2025, with topline data anticipated in 2026. Further Phase 3 studies are planned for 2026, with data expected in 2027. This candidate has received FDA Breakthrough Therapy designation for IPD and pneumonia and is designed to cover approximately 95% of IPD in U.S. adults aged 50 and older, demonstrating superior immune responses compared to the current standard, PCV20, in adult populations. The successful approval and launch of VAX-31 would tap into the adult segment of the global pneumococcal vaccine market, which is projected to grow significantly.
2. Development and Potential Commercialization of PCV Candidates for Infants: Vaxcyte is also actively pursuing its PCV franchise for the pediatric population. VAX-31 is being evaluated in a Phase 2 infant clinical program, with topline data from its ongoing dose-finding study expected by the end of the first half of 2027. Additionally, VAX-24, a 24-valent PCV candidate, is in a Phase 2 infant clinical program, with topline data from the primary immunization series expected by the end of the first quarter of 2025. While recent data for VAX-24 in infants did not meet non-inferiority criteria on multiple serotypes compared to Prevnar 20, Vaxcyte plans to optimize protein carrier allocation for Phase 3. The infant segment currently represents the largest portion of the pneumococcal vaccine market, estimated at $6 billion in annual sales.
3. Advancement of the Broader Vaccine Pipeline: Beyond its pneumococcal programs, Vaxcyte is building a robust pipeline of novel, broad-spectrum vaccines aimed at addressing other significant bacterial threats. The most advanced program in this early-stage pipeline is VAX-A1, a prophylactic vaccine candidate designed to prevent disease caused by Group A Strep, which is advancing towards the clinic. The company is also developing VAX-GI, a vaccine candidate targeting Shigella. Successful progression of these candidates through clinical trials and eventual commercialization would diversify Vaxcyte's revenue streams and open up new market opportunities.
4. Strategic Manufacturing and Global Commercial Readiness: Vaxcyte is implementing a strategic manufacturing approach to build capacity for global PCV demand. This includes a global commercial manufacturing agreement with Lonza for key components and an agreement with Thermo Fisher Scientific to establish U.S. fill-finish manufacturing, which expands domestic capacity to support future commercial efforts. These steps are crucial for ensuring the company's ability to supply vaccines once they receive regulatory approval, enabling broader market penetration and revenue generation.

Share Issuance

• In 2024, Vaxcyte raised a total of $2.2 billion in net proceeds through two equity offerings.
• One public offering in September 2024 generated approximately $1.5 billion in gross proceeds, including the full exercise of underwriters' option to purchase additional shares. This offering involved 12,087,378 shares of common stock and pre-funded warrants to purchase 2,427,184 shares.
• Vaxcyte completed another public offering in April 2023, yielding aggregate gross proceeds of $575.2 million.

Inbound Investments

• Vaxcyte received partial funding from two National Institutes of Health (NIH) research grants totaling $7.2 million for its VAX-GI vaccine candidate, reported in August 2023.
• The company's revenue primarily comes from collaboration agreements, licensing, and milestone payments for its vaccine development programs.
• In April 2020, Vaxcyte completed a Series D funding round of $110 million led by RA Capital Management and Janus Henderson Investors.

Capital Expenditures

• As of March 31, 2025, Vaxcyte had incurred $246.0 million in total capital and facility buildout expenditures for a dedicated manufacturing suite with Lonza.
• This manufacturing suite, intended to support the potential global commercialization of the company's PCV programs, is expected to be completed by early 2026 at an estimated total cost of $300-$350 million.
• For the full year 2024, capital and facility buildout expenditures related to the Lonza manufacturing suite amounted to $127.8 million.